GHR and cancer: Osmr and Ghr are known to promote cancer progression (Yu et al., 2019; Strous et al., 2020), and Tnfrsf22 (DcR2), a member of the TNF receptor superfamily, has been shown to be a receptor for TRAIL, but lacks a functional death domain (Sag et al., 2019).